The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I evaluation of sorafenib (SOR) and bevacizumab (BEV) as first-line therapy in hepatocellular cancer (HCC): North Central Cancer Treatment Group trial N0745.
J. M. Hubbard
No relevant relationships to disclose
S. R. Alberts
Consultant or Advisory Role - Bayer (U)
Research Funding - Bayer
W. S. Loui
No relevant relationships to disclose
M. R. Mahoney
No relevant relationships to disclose
L. R. Roberts
No relevant relationships to disclose
T. C. Smyrk
No relevant relationships to disclose
Z. Gatalica
No relevant relationships to disclose
S. Kumar
No relevant relationships to disclose
S. R. Dakhil
No relevant relationships to disclose
P. J. Flynn
Consultant or Advisory Role - Genentech
Honoraria - Genentech
J. M. Lafky
No relevant relationships to disclose
M. J. Bury
No relevant relationships to disclose